The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
An updated safety analysis of OCEANS, a randomized, double-blind, phase III trial of gemcitabine (G) and carboplatin (C) with bevacizumab (BV) or placebo (PL) followed by BV or PL to disease progression (PD) in patients with platinum-sensitive (Plat-S) recurrent ovarian cancer.
Carol Aghajanian
No relevant relationships to disclose
Stephanie V. Blank
No relevant relationships to disclose
Barbara Ann Goff
Honoraria - Lilly
Patricia Lynn Judson
No relevant relationships to disclose
Lawrence R. Nycum
No relevant relationships to disclose
Mika A. Sovak
Employment or Leadership Position - Genentech
Stock Ownership - Roche/Genentech
Jing Yi
Employment or Leadership Position - Genentech
Stock Ownership - Roche
Amreen Husain
Employment or Leadership Position - Genentech
Stock Ownership - Roche